MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
1.604
-0.036 (-2.21%)
Feb 21, 2025, 4:00 PM EST - Market closed
MetaVia Employees
MetaVia had 8 employees as of December 31, 2023. The number of employees increased by 6 or 300.00% compared to the previous year.
Employees
8
Change (1Y)
6
Growth (1Y)
300.00%
Revenue / Employee
n/a
Profits / Employee
-$3,466,625
Market Cap
13.82M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | 6 | 300.00% |
Dec 31, 2022 | 2 | -3 | -60.00% |
Dec 31, 2021 | 5 | -2 | -28.57% |
Dec 31, 2020 | 7 | -5 | -41.67% |
Dec 31, 2019 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
MTVA News
- 6 weeks ago - MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference - PRNewsWire
- 3 months ago - NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases - PRNewsWire
- 3 months ago - NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - PRNewsWire
- 3 months ago - NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH - PRNewsWire
- 5 months ago - NeuroBo Pharmaceuticals to Participate in Investor Conferences in October - PRNewsWire
- 5 months ago - NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity - PRNewsWire
- 6 months ago - NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - PRNewsWire